Adaptimmune Therapeutics PLC — Director's Dealing 2016

Aug 13, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-08-11

Reporting Person: Knowles Jonathan Kenneth Charles (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-11	Option to purchase Ordinary Shares	$1.27	A	217222	Acquired	2026-08-11	Ordinary Shares (217222)	Direct

Footnotes

F1: The exercise price was converted from GBP0.97 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.